score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 5	version 2	0.331						Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	COSMIC Signature 5 is associated with somatic ERCC2 mutations, which may suggest sensitivity to cisplatin based chemotherapy.	Kim J, Mouw KW, Polak P, et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet. 2016;48(6):600-606.	https://doi.org/10.1038/ng.3557													0				COSMIC Signature (version 2) 5 (33%)		KIRP-B1-5398		
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Splice Site	p.N581S	0.1778	90.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0	0.0	0.0	0.0	BRAF p.N581S (Splice Site)	1.0	KIRP-B1-5398	KIRP-B1-5398-TP	KIRP-B1-5398-NB
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Nonsense	p.K77*	0.1591	88.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0	7.0	0.5714	0.0218	MLH3 p.K77* (Nonsense)		KIRP-B1-5398	KIRP-B1-5398-TP	KIRP-B1-5398-NB
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.E103G	0.0947	95.0	0.0	0.0																Investigate Actionability	0.0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	40.0	0.25	0.5672	ASXL1 p.E103G (Missense)		KIRP-B1-5398	KIRP-B1-5398-TP	KIRP-B1-5398-NB
Biologically Relevant				Copy Number	TSC2	Amplification				0.0	0.0																					0				TSC2 Amplification		KIRP-B1-5398	TCGA-B1-5398-01	
Biologically Relevant				Copy Number	PALB2	Amplification				0.0	0.0																					0				PALB2 Amplification		KIRP-B1-5398	TCGA-B1-5398-01	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.60_61insAAAAAP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.60_61insAAAAAP (Insertion)		KIRP-B1-5398		
